Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)

Inclusion Criteria * Age \>18 years * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 * Hemoglobin A1c ≤9%, if diabetes mellitus present * If kidney transplant recipient, must have eGFR\<60 mL/min/1.73m2 and evidence of progressive kidney function loss over ≥6 months * Ability to give informed consent Exclusion Criteria * Anemia (hemoglobin \<8.5 g/dL) * Body weight \>150 kg or BMI \>50 * Uncontrolled hypertension: sustained systolic blood pressure (SBP) \>160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg despite maximal doses of at least 2 different classes of anti-hypertensive medications * Chronic hypotension history: sustained SBP \<85 mmHg * Kidney failure requiring ongoing kidney replacement therapy including hemodialysis or peritoneal dialysis * Active, high-dose immunosuppression therapy (e.g. chronic prednisone ≥20 mg daily) * Solid organ transplantation history; excluding kidney transplant * Active treatment for acute cellular rejection, in kidney transplant recipients * Recent cardiovascular event (hospitalization for myocardial infarction, stroke, congestive heart failure (NYHA class ≥III or ejection fraction ≤30%) within 3 months or uncontrolled cardiac arrhythmias (e.g. ventricular arrhythmia, supraventricular tachycardia and bradyarrhythmia) * History of liver cirrhosis * Chronic obstructive pulmonary disease or asthma requiring daily medication * History of recurring blood clotting disorder (thromboembolism: pulmonary embolism, deep venous…